GridAI Technologies (GRDX) Preferred Stock Liabilities (2024 - 2025)
GridAI Technologies' (GRDX) quarterly Preferred Stock Liabilities came in at $3.9 million in Q4 2025, down 93.68% YoY from $61.7 million in Q4 2024, and down 93.68% on a QoQ basis from $61.7 million in Q3 2025.
GridAI Technologies (GRDX) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends
GridAI Technologies (GRDX) has 2 years of Preferred Stock Liabilities data on file, last reported at $3.9 million in Q4 2025.
- Quarterly Preferred Stock Liabilities fell 93.68% year-over-year to $3.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.9 million (down 93.68% YoY) and the FY2025 annual result came in at $3.9 million, down 93.68% from the prior year.
- Preferred Stock Liabilities retreated to $3.9 million in Q4 2025, from $61.7 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $61.7 million in Q1 2024 to a low of $3.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | GridAI Technologies | 6.06 Mn | 6.06 Mn | - | 3.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.90 Mn |
| Sep 30, 2025 | 61.68 Mn |
| Jun 30, 2025 | 61.68 Mn |
| Mar 31, 2025 | 61.68 Mn |
| Dec 31, 2024 | 61.68 Mn |
| Sep 30, 2024 | 61.68 Mn |
| Jun 30, 2024 | 61.68 Mn |
| Mar 31, 2024 | 61.68 Mn |